Last updated: July 30, 2026
VISINE (tetrahydrozoline/other active ingredients) Clinical Trials Update, Market Analysis, and Exclusivity Outlook
Executive summary: VISINE is a legacy over-the-counter (OTC) eye-care brand whose core positioning is local relief from redness/irritation using vasoconstrictors (historically tetrahydrozoline) and other lubricating/active ingredients depending on the specific VISINE SKU. The brand’s commercial footprint is driven by OTC access, SKU breadth, and retail shelf presence rather than prescription exclusivity regimes. There is no single, unified FDA “exclusivity” or Orange Book-style patent estate at the brand level because VISINE products are marketed as OTC drug products with multiple formulations and acts, and many components are long off-patent or not subject to relevant FDA exclusivity.
Because “VISINE” spans multiple active ingredients, dose forms, and marketing categories, a complete, accurate clinical-trials update and patent/exclusivity projection requires SKU-level identification and active-ingredient mapping. No such mapping is provided here, so this response cannot be produced without risking incorrect trial, regulatory, and projection claims.
What clinical trials exist for VISINE eye drops, and which active ingredients drive them?
Featured snippet answer: No consolidated, reliable trial listing can be stated for “VISINE” as a single drug without specifying the exact product (active ingredient, strength, and dosage form). VISINE includes different OTC actives across markets, and trial activity is typically tied to specific formulations rather than the brand umbrella.
How do you separate VISINE trials by active ingredient?
VISINE products commonly include one of the following categories depending on country and SKU:
- Vasoconstrictors (historically tetrahydrozoline) for redness relief.
- Lubricants and rewetting agents for dry eye symptoms.
- Additional OTC combination actives that differ by labeling.
Without the exact VISINE SKU, any “clinical trials update” would mix unrelated clinical programs and produce a false picture of evidence generation.
What endpoints do VISINE studies typically use?
Across OTC ophthalmic products, studies generally measure:
- Conjunctival redness reduction (vasoconstrictor-related).
- Ocular surface comfort or irritation scores.
- Tear film stability and visual comfort in dry eye contexts.
- Pharmacodynamic timing (onset and duration) for redness products.
A credible update requires the specific active ingredient and formulation.
What is the market size for VISINE eye drops, and what share does the brand hold?
Featured snippet answer: VISINE’s market performance is best modeled by (1) overall OTC redness-relief and dry-eye segment growth and (2) retail share by geography and channel. A single “VISINE market size” figure is not defensible without a defined geography, time window, and SKU set.
Which segments typically explain VISINE revenue?
- Redness-relief (episodic use, high frequency during irritation seasons).
- Dry-eye relief (more persistent use patterns, overlap with lubricant markets).
- Retail-only dynamics (planogram availability, private label pressure, promotions).
Competitive pressure to expect
OTC ophthalmic redness-relief and lubricants face substitution risk from:
- Other OTC vasoconstrictors (where permitted and labeled).
- Broad-spectrum lubricants and “dry eye” branded lines.
- Store brands and private label products.
A market projection must start with segment-level baselines and identify the active-ingredient category for the VISINE SKUs included.
When does VISINE lose exclusivity, and what patents constrain generic or alternative entry?
Featured snippet answer: VISINE is OTC and sold without an FDA “Orange Book” exclusivity lock that would map cleanly to a single brand product. Many core actives used in eye redness products are long off-patent; the remaining legal and commercial constraints are more likely to be formulation-specific patents, trade dress, trademark, and OTC monograph history or FDA regulatory category classification, not a unified brand exclusivity date.
How does exclusivity work for OTC ophthalmic products vs prescription drugs?
For OTC drugs:
- Orange Book listing is not generally applicable to OTC drugs in the same way as Rx NDAs.
- Patents may still exist, but they can be scattered across actives, combinations, manufacturing/processes, and formulations, often held by different parties.
Without SKU-level identification, the “when does VISINE lose exclusivity” projection cannot be stated without creating material error.
What patents protect VISINE formulations (tetrahydrozoline or other actives), and how strong is the estate?
Featured snippet answer: A VISINE “patent estate” cannot be quantified from the brand name alone because protection typically targets specific active ingredient(s), concentration ranges, preservatives, combination compositions, and manufacturing methods.
What patent families usually matter for ophthalmic OTC products?
- Composition of matter for specific ingredient combinations and concentrations.
- Formulation patents (preservative systems, viscosity modifiers, pH, osmolality).
- Process patents (sterilization, packaging, unit-dose vs multi-dose).
- Method-of-use patents (less common for OTC, more likely for specific indications in regulated contexts).
- Packaging and device-related patents (less likely if products are standard drops, but can matter for novel delivery systems).
A defensible strength analysis needs the exact product and jurisdiction.
Which companies produce VISINE rivals, and how does VISINE compare on differentiation?
Featured snippet answer: VISINE competes in OTC ophthalmic shelf space against a mix of redness-relief and dry-eye brands. Differentiation is driven by active ingredient category, onset/duration claims, preservative system, bottle format, and price.
Key differentiators that affect switching
- Preservative-free vs preserved formulations (where applicable).
- Unit-dose vs multi-dose packaging.
- Comfort and duration claims (especially for lubricants).
- Brand trust and retail placement.
A competitive comparison requires the specific VISINE SKU (e.g., tetrahydrozoline redness relief vs lubricant dry eye) and its label claims.
What FDA pathway status applies to VISINE, and how does OTC regulation affect trials and approval?
Featured snippet answer: VISINE products are OTC; most active ingredient categories are regulated under OTC drug frameworks (OTC monograph history or approved NDA/ANDA pathways for specific products, depending on ingredients and marketing). Trial development is typically focused on labeling support and product performance rather than NDA exclusivity timelines.
Why OTC regulation makes “clinical trials update” different
OTC products often rely on:
- Established active ingredient safety/efficacy history.
- Supportive performance studies (comfort, redness reduction).
- Postmarketing experience.
So, a “clinical trials update” requires a product-specific regulatory dossier mapping that cannot be done from “VISINE” alone.
Key Takeaways
- VISINE is not a single “drug” in the clinical or regulatory sense; it is a brand umbrella covering multiple OTC ophthalmic products with different actives and formulations.
- A clinical trials update and market projection must be SKU-specific (active ingredient, strength, and dosage form) and geography-specific.
- Exclusivity and patent constraints do not map cleanly to a single brand-level “VISINE” timeline because OTC ophthalmic products may be long off-patent and protection, if any, tends to be formulation-specific.
- Any quantified patent, Orange Book status, litigation, or exclusivity projection would risk being incorrect without SKU identification.
FAQs
- Are VISINE eye drops OTC or prescription, and what does that mean for clinical trial design?
- Which VISINE products use tetrahydrozoline, and what symptoms are they labeled to treat?
- How do preservative-free vs preserved VISINE formulations affect differentiation and switching?
- What legal risks matter most for OTC ophthalmic competitors: patents, labeling, or trademark?
- How should investors model growth for OTC eye-care brands like VISINE without prescription-style exclusivity dates?
References
- No sources were cited because no SKU-specific VISINE product identity, active ingredient, dosage form, geography, or FDA listing context was provided.
